title: CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation.
abstract: The TRANSPEG study was a prospective study to assess the efficacy of antiviral therapy in patients with a recurrent hepatitis C virus (HCV) after liver transplantation. The influence of regulatory T-cells (Tregs) on the response to antiviral therapy was analyzed. Patients were considered as a function of their sustained virological response (SVR) at 18 months after treatment initiation. A transcriptomic analysis was performed to assess Treg markers (Tr1 and FoxP3(+)) in serum, PBMC, and liver biopsies. 100 patients had been included in the TRANSPEG study. Data from 27 of these patients were available. The results showed that the expression of CD49b (a predominant marker of Tr1) before the introduction of antiviral therapy was significantly associated with SVR. Responders displayed lower serum levels of CD49b than nonresponders (P < 0.02). These findings were confirmed in PBMC and liver biopsies even if in a nonsignificant manner for the limited number of samples. The assessment of CD49b levels is thus predictive of the response to antiviral therapy. This data suggests that CD49b may be a marker of the failure of the immune response and antiviral therapy during HCV recurrence. The assessment of CD49b could help to select patients who require earlier and more intensive antiviral therapy.
authors.affiliation: Centre de Transplantation Hépatique, Pôle Digestif, APHP, Hôpital Saint Antoine, 184 Rue de Faubourg Saint Antoine, 75012 Paris, France ; UPMC Université Paris 6, Inserm, UMR_S938, Centre de Recherche Saint Antoine, 75012 Paris, France.
authors.forename: Stenard
authors.initials: S
authors.lastname: Fabien
authors.affiliation: UMR 8161, Institut de Biologie de Lille, 1 Rue du Professeur Calmette, 59028 Lille, France.
authors.forename: Morales
authors.initials: M
authors.lastname: Olivier
authors.affiliation: UPMC Université Paris 6, Inserm, UMR_S938, Centre de Recherche Saint Antoine, 75012 Paris, France.
authors.forename: Ghazal
authors.initials: G
authors.lastname: Khaldoun
authors.affiliation: Unité de Biostatistique, Hôpital Cochin, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France.
authors.forename: Viallon
authors.initials: V
authors.lastname: Vivian
authors.affiliation: UPMC Université Paris 6, Inserm, UMR_S938, Centre de Recherche Saint Antoine, 75012 Paris, France.
authors.forename: Aoudjehane
authors.initials: A
authors.lastname: Lynda
authors.affiliation: UMR 8161, Institut de Biologie de Lille, 1 Rue du Professeur Calmette, 59028 Lille, France.
authors.forename: Ouaguia
authors.initials: O
authors.lastname: Laurissa
authors.affiliation: UMR 8161, Institut de Biologie de Lille, 1 Rue du Professeur Calmette, 59028 Lille, France.
authors.forename: Goormachtigh
authors.initials: G
authors.lastname: Gautier
authors.affiliation: Centre de Transplantation Hépatique, Pôle Digestif, APHP, Hôpital Saint Antoine, 184 Rue de Faubourg Saint Antoine, 75012 Paris, France ; UPMC Université Paris 6, Inserm, UMR_S938, Centre de Recherche Saint Antoine, 75012 Paris, France.
authors.forename: Calmus
authors.initials: C
authors.lastname: Yvon
authors.affiliation: UMR 8161, Institut de Biologie de Lille, 1 Rue du Professeur Calmette, 59028 Lille, France.
authors.forename: Delhem
authors.initials: D
authors.lastname: Nadira
authors.affiliation: Centre de Transplantation Hépatique, Pôle Digestif, APHP, Hôpital Saint Antoine, 184 Rue de Faubourg Saint Antoine, 75012 Paris, France ; UPMC Université Paris 6, Inserm, UMR_S938, Centre de Recherche Saint Antoine, 75012 Paris, France.
authors.forename: Conti
authors.initials: C
authors.lastname: Filomena
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D001706:Biopsy; D003710:Demography; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D039421:Integrin alpha2 / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects / Q000473:pathology; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012008:Recurrence; D012254:Ribavirin / Q000494:pharmacology / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D039421:Integrin alpha2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a